Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2024-04-29 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年第一季度报告" which translates to "2024 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2024. The report is unaudited as indicated. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, specifically a quarter. This matches the definition of an Interim / Quarterly Report (IR). The document length is over 10,000 characters and contains substantive financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-04-29 Chinese
益方生物第二届监事会2024年第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 2024 third meeting of the second Supervisory Board of Yifang Bio-Technology (Shanghai) Co., Ltd. It includes details about the meeting attendance, agenda items discussed, and voting results on various reports and proposals related to the 2023 annual report, financial statements, profit distribution, and other supervisory matters. The document does not contain the full annual report or financial statements themselves but rather the Supervisory Board's approval and opinions on these reports, which are to be submitted to the shareholders' meeting for further approval. The document length is short (1580 characters) and is an announcement of meeting resolutions rather than the full report. This fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about supervisory board meeting resolutions and approvals, not the actual annual report or audit report.
2024-04-25 Chinese
关于益方生物非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" (special audit report) concerning non-operating fund occupation and other related party fund transactions for the year 2023. It includes detailed tables summarizing financial data related to these transactions. The presence of an audit firm and the nature of the content indicate this is a standalone audit report focusing on specific financial audit matters rather than a full annual report or other types of filings. The document length is short (1398 characters), but it contains substantive financial data and audit findings, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2023
2024-04-25 Chinese
益方生物2024年度“提质增效重回报”行动方案
Management Reports Classification · 95% confidence The document is a detailed company action plan for the year 2024, focusing on operational improvements, R&D investment, governance, investor relations, and other strategic initiatives. It is issued by the company's board and dated April 25, 2024. The content is forward-looking and strategic rather than a financial report or earnings release. It does not contain financial statements or audit information, nor is it a transcript or voting result announcement. It is not a regulatory filing or a short announcement but a comprehensive management-level communication outlining plans and governance improvements. This fits best under Management Reports (MDA), which cover management's detailed explanation of business trends, strategies, and outlook.
2024-04-25 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司2023年度募集资金存放与使用情况的专项核查意见
Regulatory Filings
2024-04-25 Chinese
益方生物关于变更公司注册资本并修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding changes in its registered capital and amendments to its Articles of Association (公司章程). It details the increase in registered capital due to the vesting of restricted stock awards and the corresponding updates to the company's charter. The document is a formal public notice about corporate governance and capital structure changes, not a full financial report or detailed management discussion. It is not an annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting result announcement. The content fits the category of Share Issue/Capital Change announcements, as it concerns changes in registered capital and share count. The document length is short (1174 characters), consistent with an announcement rather than a full report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-04-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.